#1 Clinical Trials Search in Europe

Lymphangioma – Diagnostics

Go back

Lymphangioma is a noncancerous, fluid-filled swelling that typically appears in newborns and young children, most often on the head or neck. These unusual growths form when the lymphatic system doesn’t develop properly before birth, causing lymph fluid to collect under the skin. While many lymphangiomas require no treatment at all, understanding when and how to diagnose them is essential for families navigating this rare condition.

Introduction: Who Should Undergo Diagnostics

Parents should seek diagnostic evaluation if they notice unusual swelling or masses under their baby’s skin, especially if these appear on the head, neck, armpits, or chest. While half of all lymphangiomas are visible at birth, many others become apparent only during the first two years of life as the child grows.[1] Sometimes these growths are so small initially that they escape notice, but they may gradually become more obvious over time.

Diagnostic assessment is particularly important if the swelling grows rapidly, changes color, or appears to affect your child’s breathing, swallowing, or vision. These symptoms could indicate that the lymphangioma is putting pressure on vital structures nearby. Additionally, if your child has been diagnosed with certain genetic conditions such as Down syndrome, Turner syndrome, or Noonan syndrome, healthcare providers may recommend screening for lymphangiomas, as these conditions are associated with a higher risk of developing these malformations.[1]

Before birth, expectant mothers may learn about potential lymphangiomas through routine prenatal ultrasounds. If an ultrasound reveals an abnormal fluid-filled mass in the fetus, particularly around the neck region, further diagnostic evaluation will be recommended to understand the nature and extent of the growth.[7]

Adults rarely develop lymphangiomas, but when they do occur, they typically result from damage to previously normal lymphatic vessels caused by surgery, trauma, infection, or radiation therapy. Adults who notice new masses or persistent swelling in areas where they’ve had previous procedures should consult with their healthcare provider for appropriate diagnostic testing.[9]

Diagnostic Methods

Diagnosing lymphangioma usually begins with a thorough medical history and physical examination. Healthcare providers will ask about when the swelling first appeared, whether it has grown or changed, and if the child has experienced any symptoms such as pain, bleeding, or infection. The doctor will carefully examine the affected area, noting the size, location, texture, and appearance of the mass.[4]

The physical characteristics of lymphangiomas often provide important diagnostic clues. These growths typically feel soft and spongy to the touch, and they may appear as tiny clear, pink, or reddish-blue bumps on the skin surface. In some cases, the overlying skin contains small bubble-like structures called vesicles, which look like tiny blisters. These vesicles initially contain clear fluid, but they can turn dark red if bleeding occurs inside the lymphangioma.[4]

Ultrasound imaging is often the first diagnostic tool used to evaluate suspected lymphangiomas, particularly in pregnant women during prenatal screening. This test uses sound waves to create pictures of the inside of the body without using radiation, making it safe for both mothers and babies. Ultrasound can help identify fluid-filled masses and determine their approximate size and location.[7]

For a more detailed assessment, doctors typically recommend magnetic resonance imaging, commonly known as MRI. This advanced imaging technique uses magnets and radio waves to create highly detailed pictures of soft tissues inside the body. MRI with contrast enhancement is particularly valuable because it can show the full extent of the lymphangioma, including how deep it extends beneath the skin and whether it affects nearby organs or structures. This information is crucial for planning treatment if needed and understanding the complete anatomy of the malformation.[7]

⚠️ Important
MRI scanning is the preferred imaging method for diagnosing lymphangiomas because it provides the most comprehensive information about the malformation’s size, depth, and relationship to surrounding tissues. This detailed view helps doctors distinguish lymphangiomas from other types of growths and plan the best approach for management.

In many cases, the combination of medical history, physical examination findings, and imaging studies provides enough information to confirm the diagnosis without further testing. The diagnosis of lymphangiomas is based mainly on clinical history, physical examination findings, and imaging results.[4] Healthcare providers look for characteristic features such as the age of onset (typically birth to age 2), location (most commonly head and neck), appearance (soft, fluid-filled masses), and imaging patterns that distinguish lymphangiomas from other conditions.

When diagnostic uncertainty remains, or when the growth shows unusual features, doctors may recommend a biopsy. During this procedure, a small sample of tissue is removed from the mass and examined under a microscope in a laboratory. However, biopsies are not routinely performed for lymphangiomas because the diagnosis can usually be made based on clinical and imaging findings alone. The microscopic examination of lymphangioma tissue shows collections of abnormally enlarged lymphatic vessels filled with lymph fluid.[9]

Healthcare providers must also distinguish lymphangiomas from other conditions that can cause similar symptoms. The process of ruling out other possible diagnoses is called differential diagnosis. Conditions that may initially resemble lymphangiomas include hemangiomas (blood vessel tumors), cysts (fluid-filled sacs from other causes), certain infections, and rarely, cancerous growths. The noncancerous nature of lymphangiomas, combined with their characteristic appearance on imaging, usually allows doctors to make this distinction confidently.[3]

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials testing new treatments for lymphangiomas, additional diagnostic assessments may be required beyond standard diagnostic procedures. Clinical trials establish specific criteria to ensure that participants are appropriate candidates for the experimental treatments being studied.

Detailed imaging documentation forms a cornerstone of clinical trial enrollment criteria. Researchers typically require baseline MRI scans with precise measurements of the lymphangioma’s dimensions, including its volume, depth, and exact anatomical location. These baseline images serve as comparison points to evaluate whether the experimental treatment effectively reduces the size of the malformation over time. Some trials may also require specific types of MRI sequences or contrast protocols to standardize imaging across all study participants.[7]

Clinical trials often categorize lymphangiomas based on their characteristics, and enrollment may be limited to specific types. For instance, a trial might accept only patients with macrocystic lymphatic malformations (large cysts greater than 2 centimeters), microcystic lymphatic malformations (small cysts less than 2 centimeters), or mixed types containing both large and small cysts. Precise imaging analysis is necessary to determine which category a patient’s lymphangioma falls into.[3]

Some clinical trials require genetic testing to identify specific mutations associated with lymphangiomas. Recent research has discovered that many lymphangiomas are caused by mutations in a gene called PIK3CA, found in approximately 75-80% of cases. Trials testing treatments that target this specific genetic abnormality may require confirmation through specialized genetic testing of tissue samples before enrollment.[6]

Blood tests and general health assessments ensure that trial participants are healthy enough to receive experimental treatments safely. These may include complete blood counts to check for adequate levels of blood cells, liver and kidney function tests to ensure these organs can process medications properly, and tests to rule out active infections. If the trial involves medications that might affect the immune system, additional immune function tests may be required.

Documentation of previous treatments and their outcomes is another important qualification criterion. Trial coordinators need detailed records showing which treatments, if any, the patient has already tried, how the lymphangioma responded, and whether any complications occurred. This information helps researchers understand whether the patient represents an appropriate case for testing new interventions.

For trials evaluating treatments for lymphangiomas that cause functional problems, specific assessments of those functions become part of the qualification process. If the lymphangioma affects breathing, pulmonary function tests may be required. If it affects swallowing, specialized swallowing studies might be needed. If vision is impaired, ophthalmological examinations would be necessary. These functional assessments establish baseline measurements to determine whether the experimental treatment improves these specific problems.[1]

⚠️ Important
Clinical trial enrollment often involves more extensive diagnostic testing than standard care requires. These additional tests help researchers gather precise data about treatment effectiveness and safety. Families considering clinical trial participation should discuss with their healthcare team what specific diagnostic procedures would be required and how they differ from routine monitoring.

Quality of life assessments also play a role in clinical trial qualification. Researchers may use standardized questionnaires to evaluate how the lymphangioma affects the patient’s daily activities, social interactions, and emotional well-being before treatment begins. These assessments provide important outcome measures beyond just physical changes in the lymphangioma itself.

Prognosis and Survival Rate

Prognosis

The outlook for children with lymphangiomas is generally very positive. These growths are almost always noncancerous and are rarely life-threatening.[1] Most lymphangiomas do not cause any significant medical problems and many require no treatment at all. The prognosis depends primarily on the size and location of the malformation rather than any inherent danger from the condition itself.

Children with small lymphangiomas located away from vital structures typically have excellent outcomes with minimal impact on their daily lives. These growths may remain stable throughout childhood or even gradually become less noticeable as the child grows. Some small lymphangiomas may never cause any symptoms whatsoever.

Lymphangiomas that affect critical areas such as the airway, eyes, or vital organs may present more challenges. If a large lymphangioma in the neck region blocks the airway at birth, immediate medical intervention may be necessary. However, with appropriate management, even children with complex lymphangiomas can lead normal, healthy lives. The main long-term complications include recurrent infections in the affected area, occasional bleeding into the lymphangioma causing temporary swelling, and in some cases, overgrowth of affected tissues or bones.[1]

One important factor affecting prognosis is whether the lymphangioma is associated with genetic conditions such as Down syndrome, Turner syndrome, or Noonan syndrome. Children with these chromosomal abnormalities who also have lymphangiomas may face additional medical challenges related to their underlying genetic condition, though the lymphangioma itself follows a similar course.[1]

For lymphangiomas that require treatment, the prognosis also depends on the completeness of treatment and the specific type of lymphangioma. Complete surgical removal of superficial lymphangiomas often leads to excellent long-term results. However, deeper lymphangiomas can be more challenging to treat completely, and recurrence after treatment is possible, particularly for extensive or deep-seated malformations.[10]

Survival rate

Lymphangiomas are noncancerous malformations, not life-threatening diseases, so survival rates are not typically calculated or reported in the medical literature as they would be for cancerous conditions. The vast majority of children with lymphangiomas survive well into adulthood without any impact on their lifespan.[5]

In extremely rare cases where very large lymphangiomas critically compress vital organs such as the airway immediately after birth, life-threatening complications can occur. However, with modern medical care and early intervention, even these challenging situations can usually be managed successfully. The emphasis in lymphangioma care is on quality of life and managing complications rather than concerns about survival.

Ongoing Clinical Trials on Lymphangioma

  • Study on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +1

References

https://my.clevelandclinic.org/health/diseases/23141-lymphangioma

https://www.nicklauschildrens.org/conditions/lymphangioma

https://www.medicalnewstoday.com/articles/318628

https://emedicine.medscape.com/article/1086806-overview

https://www.merckmanuals.com/home/skin-disorders/noncancerous-skin-growths/lymphangiomas

https://en.wikipedia.org/wiki/Lymphatic_malformations

https://www.childrenshospital.org/conditions/lymphatic-malformation

https://my.clevelandclinic.org/health/diseases/23141-lymphangioma

https://www.ncbi.nlm.nih.gov/books/NBK470333/

https://emedicine.medscape.com/article/1086806-treatment

More information about
Lymphangioma:

FAQ

How can doctors tell the difference between a lymphangioma and a hemangioma?

While both can appear as masses under the skin, lymphangiomas contain clear or pale lymph fluid and typically feel softer and more spongy, whereas hemangiomas contain blood and often appear bright red or deep purple. MRI imaging shows distinct patterns for each condition—lymphangiomas demonstrate fluid-filled cystic spaces, while hemangiomas show increased blood vessel density. The timing of appearance also differs, with lymphangiomas usually present at birth or appearing within the first two years, while many hemangiomas grow rapidly during the first few months after birth and then gradually shrink on their own.

Does my child need to be sedated for diagnostic imaging tests?

For ultrasound examinations, sedation is typically not necessary because the test is painless and quick. However, for MRI scans, which require the child to remain completely still for 30 to 60 minutes inside a narrow tube, young children often need sedation or general anesthesia to ensure high-quality images. The decision depends on the child’s age, ability to cooperate, and the complexity of the scan required. Your healthcare team will discuss these options with you beforehand.

Can lymphangiomas be detected before birth?

Yes, many lymphangiomas, especially larger ones called cystic hygromas, can be detected during routine prenatal ultrasound examinations, typically during the second trimester. When a suspected lymphangioma is identified prenatally, additional ultrasounds and sometimes fetal MRI may be recommended to better understand the size and location. This early detection allows healthcare teams to prepare for any special care the baby might need immediately after birth, particularly if the lymphangioma might affect breathing.

How often does my child need follow-up imaging after diagnosis?

The frequency of follow-up imaging depends on several factors including the size, location, and behavior of the lymphangioma, as well as whether any treatment has been provided. Small, stable lymphangiomas that cause no symptoms may require imaging only once a year or even less frequently. However, if the lymphangioma is growing, causing symptoms, or has been treated, imaging may be needed every few months to monitor changes. Your healthcare provider will establish a personalized monitoring schedule based on your child’s specific situation.

Is a biopsy always necessary to confirm lymphangioma diagnosis?

No, biopsies are rarely needed for lymphangioma diagnosis. The combination of clinical examination findings (such as the soft, spongy texture and typical locations) and characteristic imaging patterns on MRI usually provides sufficient information for confident diagnosis. Biopsies are typically reserved for cases where the diagnosis remains uncertain after imaging, or when the growth shows unusual features that raise concerns about other conditions. This approach helps avoid unnecessary invasive procedures in most children.

🎯 Key takeaways

  • • Lymphangioma diagnosis often begins with simply observing the characteristic soft, spongy swelling, typically noticed at birth or within the first two years of life.
  • • MRI with contrast is the gold standard imaging test, providing detailed maps of how deep and extensive the lymphangioma is—crucial information that simple examination cannot reveal.
  • • Roughly half of all lymphangiomas on the head or neck are visible right at birth, while the rest become apparent as babies grow during their first two years.
  • • Prenatal ultrasounds can detect larger lymphangiomas before birth, allowing medical teams to prepare for specialized care if the baby might need breathing support immediately after delivery.
  • • Unlike cancerous tumors, lymphangiomas don’t require biopsy for diagnosis in most cases—their characteristic appearance on imaging tells doctors what they need to know.
  • • Clinical trials for new lymphangioma treatments require more extensive diagnostic testing than routine care, including precise measurements, genetic analysis, and detailed functional assessments.
  • • The tiny bubble-like vesicles that sometimes appear on the skin over lymphangiomas can change from clear to dark red when bleeding occurs inside—a visual clue that helps with diagnosis.
  • • Children with certain genetic conditions like Down syndrome or Turner syndrome face higher risks of developing lymphangiomas and may benefit from proactive screening.

Connected medications: